Keqian Biology(SH:688526)2023-04-17 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 279,514,834.18, representing a year-on-year increase of 37.92%[5] - The net profit attributable to shareholders for the same period was CNY 135,537,098.41, reflecting a growth of 49.33% compared to the previous year[10] - Basic and diluted earnings per share were both CNY 0.29, marking a 45.00% increase year-on-year[6] - Total operating revenue for Q1 2023 reached ¥279,514,834.18, a 38% increase from ¥202,659,616.48 in Q1 2022[20] - Net profit for Q1 2023 was ¥135,431,910.74, compared to ¥90,760,001.56 in Q1 2022, representing a 49% growth[21] - The company reported a total profit of ¥156,199,066.47 for Q1 2023, up from ¥102,776,638.28 in Q1 2022, marking a 52% increase[21] Cash Flow - The net cash flow from operating activities reached CNY 178,103,336.61, an increase of 67.43% due to higher sales revenue[6] - The net cash flow from operating activities for Q1 2023 was $178.1 million, an increase of 67.5% compared to $106.4 million in Q1 2022[24] - Cash inflow from operating activities in Q1 2023 was ¥358,807,595.18, compared to ¥296,350,484.11 in Q1 2022, indicating a 21% increase[23] - The net cash flow from investment activities was -$20.8 million, an improvement from -$92.1 million in Q1 2022[24] - Cash inflow from financing activities totaled $115.0 million, compared to $60.7 million in the same quarter last year, marking an increase of 89.5%[24] - The net increase in cash and cash equivalents for the quarter was $270.3 million, contrasting with a decrease of $14.2 million in the previous year[24] Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 4,672,235,560.78, up 6.41% from the end of the previous year[6] - The company's total assets reached CNY 4,672,235,560.78, an increase from CNY 4,390,641,791.92 on December 31, 2022, reflecting a growth of approximately 6.4%[16] - The company's total liabilities increased to CNY 769,539,959.37 from CNY 623,841,368.92, representing a rise of about 23.3%[17] - Total liabilities as of Q1 2023 amounted to ¥1,037,789,459.81, an increase from ¥891,627,601.69 in the previous year[18] Research and Development - Research and development expenses totaled CNY 21,503,347.58, a decrease of 10.16% year-on-year, with R&D expenses accounting for 7.69% of operating revenue[6] - The company is actively engaged in the research and development of various veterinary vaccines, with multiple products in different stages of clinical trials and laboratory research[15] - The company has submitted clinical trial applications for several new vaccines, including a dual inactivated vaccine for swine fever and pseudorabies, indicating a focus on expanding its product portfolio[15] - The company invested a total of RMB 10,865,581.84 in the clinical trial of the genetically engineered live vaccine for pseudorabies in pigs[14] - The company reported an investment of RMB 13,267,253.59 in the laboratory research of the genetically engineered live vaccine for infectious bovine rhinotracheitis[14] - The company has a total of 10 ongoing research projects related to veterinary products, with varying stages of progress and investment amounts[14] Shareholder Information - The company had a total of 7,887 common shareholders at the end of the reporting period[12] - The top shareholder, Wuhan Huazhong Agricultural Assets Management Co., Ltd., held 16.73% of the shares, totaling 78,004,310 shares[12] - The company has a total of 10 major shareholders, with specific shareholding details disclosed in the report[13] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[20]